These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33134417)

  • 21. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.
    Rodríguez-Rubio M; Figueira JC; Acuña-Castroviejo D; Borobia AM; Escames G; de la Oliva P
    Trials; 2020 Aug; 21(1):699. PubMed ID: 32758298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.
    McKinnon JE; Wang DD; Zervos M; Saval M; Marshall-Nightengale L; Kilgore P; Pabla P; Szandzik E; Maksimowicz-McKinnon K; O'Neill WW
    Int J Infect Dis; 2022 Mar; 116():167-173. PubMed ID: 34954095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
    Grau-Pujol B; Camprubí D; Marti-Soler H; Fernández-Pardos M; Guinovart C; Muñoz J
    Trials; 2020 Jul; 21(1):688. PubMed ID: 32727613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
    Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
    Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease.
    Griese M; Kappler M; Stehling F; Schulze J; Baden W; Koerner-Rettberg C; Carlens J; Prenzel F; Nährlich L; Thalmeier A; Sebah D; Kronfeld K; Rock H; Ruckes C; ; Wetzke M; Seidl E; Schwerk N
    Orphanet J Rare Dis; 2022 Jul; 17(1):289. PubMed ID: 35871071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.
    Eze P; Mezue KN; Nduka CU; Obianyo I; Egbuche O
    Am J Cardiovasc Dis; 2021; 11(1):93-107. PubMed ID: 33815925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials.
    Mitjà O; Reis G; Boulware DR; Spivak AM; Sarwar A; Johnston C; Webb B; Hill MD; Smith D; Kremsner P; Curran M; Carter D; Alexander J; Corbacho M; Lee TC; Hullsiek KH; McDonald EG; Hess R; Hughes M; Baeten JM; Schwartz I; Metz L; Richer L; Chew KW; Daar E; Wohl D; Dunne M
    Clin Transl Sci; 2023 Mar; 16(3):524-535. PubMed ID: 36601684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.
    Gommans DHF; Nas J; Pinto-Sietsma SJ; Koop Y; Konst RE; Mensink F; Aarts GWA; Konijnenberg LSF; Cortenbach K; Verhaert DVM; Thannhauser J; Mol JQ; Rooijakkers MJP; Vos JL; van Rumund A; Vart P; Hassing RJ; Cornel JH; de Jager CPC; van den Heuvel MM; van der Hoeven HG; Verbon A; Pinto YM; van Royen N; van Kimmenade RRJ; ; de Leeuw PW; van Agtmael MA; Bresser P; ; van Gilst WH; Vonk-Noordergraaf A; Tijssen JGP; ; van Royen N; de Jager CPC; van den Heuvel MM; van der Hoeven HG; Verbon A; Pinto YM; van Kimmenade RRJ
    Am Heart J; 2020 Aug; 226():60-68. PubMed ID: 32512291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.
    Lother SA; Abassi M; Agostinis A; Bangdiwala AS; Cheng MP; Drobot G; Engen N; Hullsiek KH; Kelly LE; Lee TC; Lofgren SM; MacKenzie LJ; Marten N; McDonald EG; Okafor EC; Pastick KA; Pullen MF; Rajasingham R; Schwartz I; Skipper CP; Turgeon AF; Zarychanski R; Boulware DR
    Can J Anaesth; 2020 Sep; 67(9):1201-1211. PubMed ID: 32383125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.
    Almazrou SH; Almalki ZS; Alanazi AS; Alqahtani AM; Alghamd SM
    Saudi Pharm J; 2020 Dec; 28(12):1877-1882. PubMed ID: 33020690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 'myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19' is far from reality.
    Dhibar DP; Arora N; Chaudhary D; Prakash A; Medhi B; Singla N; Mohindra R; Suri V; Bhalla A; Sharma N; Singh MP; Lakshmi PVM; Goyal K; Ghosh A
    Sci Rep; 2023 Jan; 13(1):378. PubMed ID: 36611040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Efficacy of Hydroxychloroquine and Azithromycin Combination Therapy on Hospital Mortality in COVID 19 Pneumonia Patients.
    Özuygur Ermiş SS; Ergan B; Kaçmaz Başoğlu Ö; Ercan S; Korkmaz Ekren P; Kuruüzüm Z; Özhan MH; Sayiner AA; Savran Y; Sertöz ŞR; Taşbakan MS; Kilinç O; Sayiner A
    Turk J Med Sci; 2021 Aug; ():. PubMed ID: 34344140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial.
    Ried K; BinJemain T; Sali A
    Cureus; 2021 Nov; 13(11):e19902. PubMed ID: 34976511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
    Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
    Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
    Giaime P; Guenoun M; Pedinielli N; Narbonne H; Bergounioux JP; Solas C; Guilhaumou R; Sampol J; Ollier J; Sichez H; Serveaux M; Brunner F; Bataille S
    Nephrol Dial Transplant; 2020 Aug; 35(8):1346-1353. PubMed ID: 32844224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19.
    Zhanel GG; Zhanel MA; Boreskie KF; Lynch JP; Karlowsky JA
    Can J Infect Dis Med Microbiol; 2021; 2021():5942366. PubMed ID: 34557260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial.
    Griese M; Köhler M; Witt S; Sebah D; Kappler M; Wetzke M; Schwerk N; Emiralioglu N; Kiper N; Kronfeld K; Ruckes C; Rock H; Anthony G; Seidl E
    Trials; 2020 Apr; 21(1):307. PubMed ID: 32245508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
    COVID-19 RISK and Treatments (CORIST) Collaboration
    Eur J Intern Med; 2020 Dec; 82():38-47. PubMed ID: 32859477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.